Selva Therapeutics

Selva Therapeutics is a privately-held biotechnology company dedicated to developing infectious disease therapeutics. The company’s lead candidate, SLV213, is a novel small-molecule antiviral therapy active against multiple viruses that threaten global health, including SARS-CoV-2 (the coronavirus that causes COVID-19). Additionally, SLV213 demonstrates activity against Ebola virus, Nipah virus, and Chagas disease, a parasitic disease endemic in South and Central America but also found in the southern United States. By expediting the development of SLV213 for COVID-19, Selva Therapeutics aims to introduce a valuable treatment option with the potential to combat various life-threatening infectious diseases and safeguard global health.